Medpace (NASDAQ:MEDP) CEO August Troendle Sells 11,366 Shares of Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 11,366 shares of Medpace stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $601.53, for a total value of $6,836,989.98. Following the sale, the chief executive officer directly owned 604,436 shares in the company, valued at approximately $363,586,387.08. This trade represents a 1.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Medpace Trading Down 0.6%

Shares of NASDAQ:MEDP opened at $578.50 on Friday. The company has a 50 day moving average of $536.23 and a 200-day moving average of $492.35. The firm has a market cap of $16.15 billion, a P/E ratio of 33.91, a P/E/G ratio of 2.60 and a beta of 1.15. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business’s revenue was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Equities research analysts forecast that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Institutional Trading of Medpace

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in shares of Medpace in the 2nd quarter valued at $1,323,047,000. AQR Capital Management LLC increased its position in shares of Medpace by 31.6% during the fourth quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock worth $758,061,000 after acquiring an additional 324,293 shares in the last quarter. Wasatch Advisors LP raised its stake in shares of Medpace by 14.0% in the 2nd quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock valued at $296,853,000 after purchasing an additional 116,354 shares during the period. Geode Capital Management LLC raised its position in Medpace by 3.8% in the 4th quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock valued at $374,836,000 after buying an additional 24,625 shares during the last quarter. Finally, Invesco Ltd. raised its holdings in shares of Medpace by 18.9% in the third quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock valued at $276,313,000 after purchasing an additional 85,517 shares during the last quarter. 77.98% of the stock is owned by institutional investors.

Analysts Set New Price Targets

MEDP has been the topic of a number of recent research reports. Truist Financial raised their price target on shares of Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a report on Friday, July 24th. TD Cowen increased their price target on shares of Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a report on Friday, July 24th. Leerink Partners set a $620.00 price objective on Medpace in a report on Thursday, July 23rd. Jefferies Financial Group cut Medpace from a “buy” rating to a “hold” rating and boosted their price objective for the company from $490.00 to $515.00 in a research report on Tuesday, July 7th. Finally, Weiss Ratings upgraded Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday. Three equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $584.18.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.